Elobixibat - Albireo AB

Drug Profile

Elobixibat - Albireo AB

Alternative Names: A 3309; AJG 533

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Albireo Pharma; EA Pharma
  • Class 2 ring heterocyclic compounds; Amides; Carboxylic acids; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Constipation
  • Phase II Irritable bowel syndrome
  • Discontinued Dyslipidaemias

Most Recent Events

  • 14 Nov 2017 Albireo expects a decision from the Japanese Pharmaceuticals and Medical Devices Agency on the approval of elobixibat for Constipation in Japan in the first half of 2018
  • 06 May 2017 Efficacy and adverse event data from a phase-IIb trial in Constipation presented at Digestive Disease Week 2017 (DDW-2017)
  • 31 Mar 2017 Ajinomoto completes a phase III trial in Constipation in Japan (PO) (JapicCTI153061)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top